LegalizeVyhláška Ministerstva zdravotnictví, kterou se mění vyhláška Ministerstva zdravotnictví č. 57/1997 Sb., kterou se stanoví léčivé přípravky plně hrazené z veřejného zdravotního pojištění a výše úhrad jednotlivých léčivých látek, ve znění pozdějších předpisů
| 254.1 | J01DA03 | cefalotin | parent. | 4 | GM | 188,18 | U/ATB |
|---|---|---|---|---|---|---|---|
| 85512 | CEFALOTIN BIOTIKA | inj sic 50x1gm | BTA | SK | |||
| 254.2 | J01DA04 | cefazolin | parent. | 3 | GM | 149,40 | U/ATB |
| 02205 | CEFAZOLINE PANPHARMA | inj sic 25x1gm | LPA | F | |||
| 85510 | VULMIZOLIN 1.0 | inj sic 50x1gm | BTA | SK | |||
| 91148 | VULMIZOLIN 1.0 | inj sic 10x1gm | BTA | SK | |||
| 84018 | CEFAZOLINE PANPHARMA | inj sic 50x1gm | LPA | F | |||
| 83111 | ORIZOLIN 1000 | inj sic 1x1000mg | CAI | IND | |||
| 254.3 | J01DA05 | cefoxitin | parent. | 6 | GM | 937,79 | U/ATB |
| 254.4 | J01DA06 | cefuroxim | parent. | 4 | GM | 439,20 | U/ATB |
| 64835 | AXETINE 750MG | inj sic 10x750mg | MOE | CY | |||
| 64832 | AXETINE 1.5GM | inj sic 50x1.5gm | MOE | CY | |||
| 64833 | AXETINE 1.5GM | inj sic 100x1.5gm | MOE | CY | |||
| 64831 | AXETINE 1.5GM | inj sic 10x1.5gm | MOE | CY | |||
| 64830 | AXETINE 1.5GM | inj sic 1x1.5gm | MOE | CY | |||
| 64837 | AXETINE 750MG | inj sic 100x750mg | MOE | CY | |||
| 254.5 | J01DA07 | cefamandol | parent. | 6 | GM | 615,68 | U/ATB |
| 254.6 | J01DA10 | cefotaxim do 1 g včetně v jedné ampuli | parent. | 6 | GM | 524,01 | U/ATB |
| 05770 | TAXCEF | inj sic 1x1gm | RXY | IND | |||
| 94176 | CEFOTAXIME | inj 1x1gm | LEK | SLO | |||
| 254.7 | J01DA10 | cefotaxim nad 1 g v jedné ampuli | parent. | 6 | GM | 459,00 | U/ATB |
| 05748 | TAXCEF 2G | inj sic 1x2gm | RXY | IND | |||
| 254.8 | J01DA11 | ceftazidim do 500 mg včetně v jedné ampuli | parent. | 6 | GM | 1736,18 | U/ATB |
| 254.9 | J01DA11 | ceftazidim nad 500 mg v jedné ampuli | parent. | 6 | GM | 1739,99 | U/ATB |
| 254.10 | J01DA12 | cefsulodin | parent. | 6 | GM | 615,68 | U/ATB |
| 254.11 | J01DA13 | ceftriaxon | parent. | 2 | GM | 555,00 | ambulantně: K/P ústavně: U/ATB |
| 64638 | OFRAMAX 1 G | inj sic 1x1gm | RXY | IND | |||
| 80662 | LENDACIN 1GM | inj sic 5x1gm | LEK | SLO | |||
| 254.12 | J01DA22 | ceftizoxim | parent. | 4 | GM | 615,68 | U/ATB |
| 254.13 | J01DA24 | cefepim | parent. | 4 | GM | 1605,91 | U/ATB |
| 254.14 | J01DA30 | cefapirin | parent. | 4 | GM | 194,73 | U/ATB |
| 254.15 | J01DA32 | cefoperazon | parent. | 6 | GM | 1526,24 | U/ATB |
| 254.16 | J01DA37 | cefpirom | parent. | 4 | GM | 1638,40 | U/ATB |
| 86598 | CEFROM 2GM | inj sic 1x2gm | ROU | F | |||
| 255 | J01DF | monobaktámová antibiotika | parent. | U/ATB | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 255.1 | J01DF01 | aztreonam | parent. | 4 | GM | 1645,60 | U/ATB |
| 86412 | AZACTAM | inj sic 1x1gm | BMS | I | |||
| 256 | J01DH | karbapenemová antibiotika | parent. | U/ATB | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 256.1 | J01DH02 | meropenem | parent. | 2 | GM | 2194,52 | U/ATB |
| 83487 | MERONEM 500MG I.V. | inj sic 10x500mg | ZNC | GB | |||
| 256.2 | J01DH51 | imipenem a inhibitor enzymu | parent. | 2 | GM | 2238,99 | U/ATB |
| 12091 | TIENAM I.M. | inj sic 1x500/500mg | MSD | CH | |||
| 257 | J01EB | krátkodobě působící sulfonamidy | p.o. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 257.1 | J01EA01 | trimethoprim (do 100 mg v jedné tabletě včetně) | p.o. | 0.4 GM | 11,88 | ||
| 89813 | TRIPRIM 100MG | tbl 20x100mg | MCK | D | |||
| 89812 | TRIPRIM 100MG | tbl 10x100mg | MCK | D | |||
| 257.2 | J01EA01 | trimethoprim (nad 100 mg v jedné tabletě) | p.o. | 0.4 | GM | 8,94 | |
| 89816 | TRIPRIM 200MG | tbl 20x200mg | MCK | D | |||
| 89815 | TRIPRIM 200MG | tbl 10x200mg | MCK | D | |||
| 257.3 | J01EB05 | sulfafurazol | p.o. | 4 | GM | 13,64 | |
| 258 | J01EE | sulfonamidy kombinované s trimetoprimem | p.o. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 258.1 | J01EE01 | sulfamethoxazol a trimethoprim (pevné lékové formy, do 120 mg v jedné tabletě včetně) | p.o. | 1.92 | GM | 17,06 | |
| 258.2 | J01EE01 | sulfamethoxazol a trimethoprim (pevné lékové formy nad 120 mg v jedné tabletě) | p.o. | 1.92 | GM | 6,84 | |
| 75023 | COTRIMOXAZOL AL FORTE | tbl 20x960mg | APA | D | |||
| 75022 | COTRIMOXAZOL AL FORTE | tbl 10x960mg | APA | D | |||
| 87758 | ORIPRIM | tbl 100x480mg | CAI | IND | |||
| 12917 | BISMORAL 480 | tbl 20x480mg | SLO | SK | |||
| 97868 | ORIPRIM | tbl 20x480mg | CAI | IND | |||
| 258.3 | J01EE01 | sulfamethoxazol a trimethoprim (tekuté lékové formy) | p.o. | 1.92 | GM | 22,39 | |
| 258.4 | J01EE03 | sulfametrol a trimethoprim (pevné lékové formy) | p.o. | 1.92 | GM | 6,94 | |
| 258.5 | J01EE03 | sulfametrol a trimethoprim (tekuté lékové formy) | p.o. | 1.92 | GM | 23,07 | |
| 258.6 | J01EE04 | sulfamonoxol a trimethoprim (pevné lékové formy) | p.o. | 1.92 | GM | 6,94 | |
| 258.7 | J01EE04 | sulfamonoxol a trimethoprim (tekuté lékové formy) | p.o. | 1.92 | GM | 23,07 | |
| 258.8 | J01EE05 | sulfadimidin a trimethoprim (pevné lékové formy) | p.o. | 1.92 | GM | 6,94 | |
| 259 | J01EE | sulfonamidy kombinované s trimetoprimem | parent. | K | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 259.1 | J01EE01 | sulfamethoxazol a trimethoprim | parent. | 1.92 | GM | 127,04 | K |
| 91281 | PRIMOTREN I.V. | inj 10x5ml | LEK | SLO | |||
| 260 | J01FA | makrolidová antibiotika | p.o. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 260.1 | J01FA | telithromycin | p.o. | 800 | MG | 96,80 | U/ATB |
| 260.2 | J01FA01 | erythromycin (pevné lékové formy) | p.o. | 1 | GM | 20,09 | |
| 260.3 | J01FA01 | erythromycin (tekuté lékové formy) | p.o. | 1 | GM | 45,61 | |
| 97508 | ERYTHROMYCIN-RATIO.TS 200MG/5ML | plv sus 1x100ml | MCK | D | |||
| 55584 | MEROMYCIN 200MG/5ML | plv sus 1x60ml | MCK | D | |||
| 55585 | MEROMYCIN 200MG/5ML | plv sus 1x100ml | MCK | D | |||
| 260.4 | J01FA02 | spiramycin | p.o. | 3 | GM | 48,42 | |
| 260.5 | J01FA05 | oleandomycin | p.o. | 1 | GM | 15,36 | |
| 260.6 | J01FA06 | roxithromycin (do 100 mg v jedné tabletě včetně) | p.o. | 0.3 | GM | 43,77 | |
| 260.7 | J01FA06 | roxithromycin (nad 100 mg v jedné tabletě) | p.o. | 0.3 | GM | 37,84 | |
| 260.8 | J01FA07 | josamycin (pevné lékové formy) | p.o. | 2 | GM | 34,05 | |
| 260.9 | J01FA07 | josamycin (tekuté lékové formy) | p.o. | 1 | GM | 42,58 | |
| 260.10 | J01FA09 | klarithromycin (pevné lékové formy) | p.o. | 0.5 | GM | 48,40 | |
| 53282 | FROMILID 250 | tbl obd 14x250mg | KRK | SLO | |||
| 53283 | FROMILID 500 | tbl obd 14x500mg | KRK | SLO | |||
| 260.11 | J01FA09 | klarithromycin (tekuté lékové formy) | p.o. | 0.5 | GM | 70,00 | |
| 260.12 | J01FA10 | azithromycin (pevné lékové formy do 125 mg v 1 tabletě nebo tobolce včetně) | p.o. | 0.25 | GM | 63,77 | |
| 260.13 | J01FA10 | azithromycin (pevné lékové formy nad 125 mg v 1 tabletě nebo tobolce) | p.o. | 0.25 | GM | 63,27 | |
| 260.14 | J01FA10 | azithromycin (tekuté lékové formy) | p.o. | 0.25 | GM | 86,60 | |
| 260.15 | J01FA13 | dirythromycin | p.o. | 0.5 | GM | 48,42 | |
| 260.16 | J01RA | kombinace antibakteriálních léčiv (spiramycin/ metronidazol) | p.o. | 5 | DF | 32,16 | |
| 261 | J01FA | makrolidová antibiotika | parent. | K | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 261.1 | J01FA01 | erythromycin | parent. | 1 | GM | 717,50 | K |
| 261.2 | J01FA02 | spiramycin | parent. | 4,5 | MU | 663,67 | K |
| 78174 | ROVAMYCINE 1.5 M.I.U. | plv inf 1x1.5mu | RSL | F | |||
| 261.3 | J01FA09 | klaritromycin | parent. | 1 | GM | 861,00 | K |
| 262 | J01FF | linkosamidová antibiotika | p.o. | ATB | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 262.1 | J01FF01 | klindamycin (pevné lékové formy) | p.o. | 1.2 | GM | 55,46 | |
| 56867 | KLIMICIN 300MG | cps 16x300mg | LEK | SLO | |||
| 03365 | DALACIN C | cps 16x150mg | UPJ | B | |||
| 94574 | KLIMICIN | cps 16x150mg | LEK | SLO | |||
| 83458 | DALACIN C | cps 16x300mg | UPJ | B | |||
| 262.2 | J01FF01 | klindamycin (tekuté lékové formy) | p.o. | 1.2 | GM | 136,53 | |
| 262.3 | J01FF02 | linkomycin (pevné lékové formy) | p.o. | 1.8 | GM | 29,08 | ATB |
| 91997 | NELOREN | cps 16x500mg | LEK | SLO | |||
| 262.4 | J01FF02 | linkomycin (tekuté lékové formy) | p.o. | 1.8 | GM | 160,62 | ATB |
| 263 | J01FF | linkosamidová antibiotika | parent. | U/ATB | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 263.1 | J01FF01 | klindamycin (do 0,3 gm včetně v jedné ampuli) | parent. | 1.8 | GM | 598,67 | U/ATB |
| 263.2 | J01FF01 | klindamycin (nad 0,3 gm v jedné ampuli) | parent. | 1.8 | GM | 548,92 | U/ATB |
| 263.3 | J01FF02 | linkomycin | parent. | 1.8 | GM | 49,17 | U/ATB |
| 263.4 | J01FG02 | quinupristin v kombinaci s dalfopristinem | parent | 1 | DF | 2492,00 | U/ATB |
| 264 | J01GA | streptomycin a jeho deriváty | parent. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 264.1 | J01GA01 | streptomycin | parent. | 1 | GM | 117,10 | |
| 59732 | STREPTOMYCIN GRUNENTHAL 1.0 G | inj sic 1x1gm+solv. | GRU | D | |||
| 265 | J01GB | aminoglykosidová antibiotika | parent. | U/ATB | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 265.1 | J01GB01 | tobramycin (do 40 mg v jedné ampuli včetně) | parent. | 0.24 | GM | 43,84 | U/ATB |
| 265.2 | J01GB01 | tobramycin (nad 40 mg v jedné ampuli) | parent. | 0.24 | GM | 23,02 | U/ATB |
| 265.3 | J01GB03 | gentamicin (do 40 mg v jedné ampuli včetně) | parent. | 0.24 | GM | 45,18 | U/ATB |
| 265.4 | J01GB03 | gentamicin (nad 40 mg v jedné ampuli) | parent. | 0.24 | GM | 23,61 | U/ATB |
| 265.5 | J01GB03 | gentamicin (lékové formy pěny) | lok. | 130 | MG | 2411,98 | U/ATB |
| 265.6 | J01GB03 | gentamicin (lékové formy kuliček k impiantaci) | imp. | 1 | DF | 152,06 | U/ATB |
| 265.7 | J01GB05 | neomycin | parent. | 1 | GM | 122,34 | U/ATB |
| 265.8 | J01GB06 | amikacin (do 100 mg v jedné ampuli včetně) | parent. | 1 | GM | 741,01 | U/ATB |
| 265.9 | J01GB06 | amikacin (nad 100 mg v jedné ampuli) | parent. | 1 | GM | 398,66 | U/ATB |
| 265.10 | J01GB07 | netilmicin (do 50 mg v jedné ampuli včetně) | parent. | 0.35 | GM | 519,93 | U/ATB |
| 265.11 | J01GB07 | netilmicin (nad 50 mg v jedné ampuli) | parent. | 0.35 | GM | 304,57 | U/ATB |
| 265.12 | J01GB11 | isepamicin (do 250 mg včetně v jedné ampuli) | parent. | 1 | GM | 620,27 | U/ATB |
| 265.13 | J01GB11 | isepamicin (nad 250 mg v jedné ampuli) | parent. | 1 | GM | 516,90 | U/ATB |
| 266 | J01MA | fluorované chinolony | p.o. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
K léčbě sparfloxacinem a trovafloxacinem je třeba konzultace a schválení antibiotického střediska.
| 266.1 | J01MA01 | ofloxacin | p.o. | 0.4 | GM | 24,50 | | | 12349 | ZANOCIN 200MG | tbl obd 10x200mg | RXY | IND | | | | | 266.2 | J01MA02 | Ciprofloxacin | p.o. | 1 | GM | 24,50 | | | 87104 | CIFLOXINAL | tbl obd 10x250mg | PMP | CZ | | | | | 44985 | CIPLOX 500 | tbl obd 10x500mg | CIA | IND | | | | | 53715 | CIFLOXINAL | tbl obd 200x250mg | PMP | CZ | | | | | 87105 | CIFLOXINAL | tbl obd 20x250mg | PMP | CZ | | | | | 53201 | CIPHIN 250 | tbl obd 10x250mg | SLO | SK | | | | | 44986 | CIPLOX 500 | tbl obd 50x500mg CIA | IND | | | | | | 44988 | CIPLOX 250 | tbl obd 10x250mg | CIA | IND | | | | | 44989 | CIPLOX 250 | tbl obd 50x250mg | CIA | IND | | | | | 53202 | CIPHIN 500 | tbl obd 10x500mg | SLO | SK | | | | | 69195 | CIPROBID 250 | tbl obd 10x250mg | CAI | IND | | | | | 96039 | CIPRINOL 500 | tbl obd 10x500mg | KRK | SLO | | | | | 94453 | CIPRINOL 250 | tbl obd 10x250mg | KRK | SLO | | | | | 69196 | CIPROBID 500 | tbl obd 10x500mg | CAI | IND | | | | | 266.3 | J01MA03 | pefloxacin | p.o. | 0.8 | GM | 24,50 | | | 94156 | ABAKTAL | tbl obd 10x400mg | LEK | SLO | | | | | 266.4 | J01MA04 | enoxacin | p.o. | 0.8 | GM | 20,50 | | | | | | | | | | | | 266.5 | J01MA06 | norfloxacin | p.o. | 0.8 | GM | 20,50 | | | 44091 | GYRABLOCK 400 | tbl obd 1000x400mg | MOE | CY | | | | | 93465 | NOLICIN | tbl 20x400mg | KRK | SLO | | | | | 266.6 | J01MA07 | lomefloxacin | p.o. | 0.8 | GM | 24,50 | | | | | | | | | | | | 266.7 | J01MA08 | fleroxacin | p.o. | 0.4 | GM | 24,50 | | | | | | | | | | | | 266.8 | J01MA09 | sparfloxacin | p.o. | 0.2 | GM | 24,50 | P | | | | | | | | | | | 266.9 | J01MA12 | levofloxacin do 250 mg v jedné tabletě včetně | p.o. | 0,25 | GM | 75,00 | U/ATB | | | | | | | | | | | 266.10 | J01MA12 | levofloxacin nad 250 mg v jedné tabletě | p.o. | 0,25 | GM | 60,00 | U/ATB | | | | | | | | | | | 266.11 | J01MA | trovafloxacin | p.o. | 0,2 | GM | 24,50 | P | | | | | | | | | | | 266.12 | J01MB05 | kyselina oxolinová | p.o. | 1 | GM | 8,91 | | | 91101 | DESUROL | tbl 50x250mg | LEX | CZ | | | | | 267 | J01MA | fluorované chinolony | parent. | U/ATB | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 267.1 | J01MA01 | ofloxacin | parent. | 0.4 | GM | 212,23 | U/ATB | | 66137 | OFLOXIN INF | inf 1x100ml/200mg | LEX | CZ | | | | | 267.2 | J01MA02 | ciprofloxacin - infúze | parent. | 0.5 | GM | 212,23 | U/ATB | | 59829 | CIPRINOL 100MG/50ML | inf 1x50ml/100mg | KRK | SLO | | | | | 59830 | CIPRINOL 200MG/100ML | inf 1x100ml/200mg | KRK | SLO | | | | | 267.3 | J01MA02 | ciprofloxacin - injekce | parent. | 0.5 | GM | 190,00 | U/ATB | | | | | | | | | | | 267.4 | J01MA03 | pefloxacin | parent. | 0.8 | GM | 93,26 | U/ATB | | 94155 | ABAKTAL | inj 10x5ml/400mg | LEK | SLO | | | | | 267.5 | J01MA08 | fleroxacin | parent. | 0.4 | GM | 212,23 | U/ATB | | | | | | | | | | | 267.6 | J01MA12 | levofloxacin | parent | 0,25 | GM | 477,00 | U/ATB | | | | | | | | | | | 267.7 | J01MA | trovafloxacin | parent. | 0,2 | GM | 212,23 | U/ATB | | 268 | J01XA | ostatní antibiotika | parent. | U/ATB | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 268.1 | J01XA01 | vankomycin | parent. | 2 | GM | 1265,30 | U/ATB | | 92290 | EDICIN 1GM | inj.sicc.1x1gm | LEK | SLO | | | | | 92289 | EDICIN 0.5GM | inj.sicc.1x500mg | LEK | SLO | | | | | 268.2 | J01XA02 | teikoplanin | parent. | 0.4 | GM | 2492,83 | U/ATB | | | | | | | | | | | 268.3 | J01XB01 | kolistin | parent. | 3 | MU | 109,34 | U/ATB | | 61178 | COLIMYCINE | inj sic 50x1mu | RBE | F | | | | | 268.4 | J01XB02 | polymyxin | parent. | 0.15 | GM | 103,09 | U/ATB | | | | | | | | | | | 268.5 | J01XX08 | linezolid | p.o. | 1,2 | GM | 4958,00 | U/ATB | | | | | | | | | | | 268.6 | J01XX08 | linezolid | parent | 1,2 | GM | 4958,00 | U/ATB | | 269 | J01XB | polymyxinová antibiotika | p.o. | U/ATB | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 269.1 | J01XB01 | kolistin | p.o. | 3 | MU | 42,82 | U/ATB | | 270 | J01XD | imidazolová chemoterapeutika | parent. | U | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 270.1 | J01XD01 | metronidazol | parent. | 1.5 | GM | 176,89 | U | | | | | | | | | | | 270.2 | J01XD03 | ornidazol | parent. | 1 | GM | 50,44 | U | | | | | | | | | | | 270.3 | J01XE01 | nitrofurantoin | p.o. | 0.2 | GM | 3,65 | | | 90510 | FURANTOIN LECIVA | tbl ent 20x100mg | LEX | CZ | | | | | 271 | J02AA | antimykotická antibiotika | parent. | U | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 271.1 | J02AA01 | amfotericin | parent. | 35 | MG | 279,36 | U | | 57548 | AMPHOTERICIN B SQUIBB | inj sic 1x50mg | BMJ | F | | | | | 271.2 | J02AA01 | amfotericin na tukových nosičích | parent. | 35 | MG | 1597,70 | U/ATB | | 272 | J02AB | imidazolová antimykotika | p.o. | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 272.1 | J02AB02 | ketokonazol | p.o. | 0.2 | GM | 27,37 | | | 54516 | NIZORAL | tbl 30x200mg | JAG | I | | | | | 91739 | ORONAZOL | tbl 20x200mg | KRK | SLO | | | | | 31109 | NIZORAL | tbl 10x200mg | JAG | I | | | | | 273 | J02AB | imidazolová antimykotika | parent. | U | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 273.1 | J02AB01 | mikonazol | parent. | 1 | GM | 469,63 | U | | 274 | J02AC | triazolová antimykotika | p.o. | P | | | |
-
- Krátkodobou léčbu ordinuje gynekolog nebo dermatolog na základě kultivačního nebo mikroskopického vyšetření:
- a) vaginální mykózy nereagující na lokálně aplikovaná antimykotika
- b) recidivy vaginálních mykóz
-
- Vícedenní léčbu ordinuje infekcionista, hematolog, onkolog, specialista pracující na transplantačních jednotkách nebo dermatolog:
- a) systémové mykózy u imunokompromitovaných pacientů
- b) těžké formy slizničních a kožních mykóz vyvolaných kandidami nebo dermatofyty na základě kultivačního nebo mikroskopického vyšetření
- c) těžké formy nehtových mykóz (itrakonazol), platí-li alespoň jedna z následujících podmínek:
• postižení celé nehtové ploténky
• postižení minimálně čtyř nehtových plotének tak, že každá z nich má postižení zasahující více než 30% za volný okraj nehtu proximálním směrem
• postižení nehtu palce dolní končetiny
Podmínkou zahájení léčby ad c) je pozitivní mikroskopický nález a provedený odběr na mykologickou kultivaci.
- d) profylakticky u imunokompromitovaných pacientů nebo u pacientů před provedením transplantace
- e) itrakonazol tekuté lékové formy - léčba orální a oesophageální kandidózy a profylakticky u imunokompromitovaných pacientů
| 274.1 | J02AC01 | flukonazol ( pevné lékové formy 150 mg v 1 tabletě ) | p.o. | 0.15 | GM | 203,85 | P | | 10743 | MYCOSYST 150 MG | cps 4x150mg | GED | H | | | | | 53917 | FLUCONAZOL 150-SLOVAKOFARMA | cps 1x150mg | SLO | SK | | | | | 66039 | MYCOMAX 150 | cps 1x150mg | LEX | CZ | | | | | 59876 | MYCOSYST 150MG | cps 2x150mg | GED | H | | | | | 59875 | MYCOSYST 150MG | cps 1x150mg | GED | H | | | | | 59788 | DIFLAZON 150 | cps 1x150mg | KRK | SLO | | | | | 274.2 | J02AC01 | flukonazol - ostatní pevné lékové formy jiné než 150 mg v jedné tabletě | p.o. | 0.2 | GM | 262,18 | P | | 59786 | DIFLAZON 50 | cps 7x50mg | KRK | SLO | | | | | 59874 | MYCOSYST 100MG | cps 28x100mg | GED | H | | | | | 59873 | MYCOSYST 50MG | cps 7x50mg | GED | H | | | | | 59790 | DIFLAZON 200 | cps 20x200mg | KRK | SLO | | | | | 59789 | DIFLAZON 200 | cps 7x200mg | KRK | SLO | | | | | 59787 | DIFLAZON 100 | cps 28x100mg | KRK | SLO | | | | | 55396 | FLUCONAZOL 50-SLOVAKOFARMA | cps 7x50mg | SLO | SK | | | | | 66033 | MYCOMAX 50 | cps 28x50mg | LEX | CZ | | | | | 66036 | MYCOMAX 100 | cps 28x100mg | LEX | CZ | | | | | 55397 | FLUCONAZOL 50-SLOVAKOFARMA | cps 14x50mg | SLO | SK | | | | | 66037 | MYCOMAX 100 | cps 7x100mg | LEX | CZ | | | | | 66032 | MYCOMAX 50 | cps 7x50mg | LEX | CZ | | | | | 274.3 | J02AC01 | flukonazol (do 50 mg v 5 ml sirupu včetně) | p.o. | 0.2 GM | 479,01 | P | | | 66031 | MYCOMAX SIR | sir 1x100ml/500mg | LEX | CZ | | | | | 64950 | DIFLUCAN 50MG/5ML | plv pro sus 1x35ml | PFC | F | | | | | 274.4 | J02AC01 | flukonazol (nad 50 do 100mg v 5 ml sirupu včetně) | p.o. | 0.2 | GM | 436,59 | P | | | | | | | | | | | 274.5 | J02AC01 | flukonazol - tekuté lékové formy nad 100 mg v 5 ml sirupu | p.o. | 0.2 | GM | 349,25 | P | | | | | | | | | | | 274.6 | J02AC02 | itrakonazol (pevné lékové formy do 400 mg včetně v jednom baleni) | p.o. | 0.2 | GM | 95,60 | P | | | | | | | | | | | 274.7 | J02AC02 | itrakonazol (pevné lékové formy) nad 400 mg v jednom balení | p.o. | 0.2 | GM | 120,00 | P | | | | | | | | | | | 274.8 | J02AC02 | itrakonazol (tekuté lékové formy) | p.o. | 0.2 | GM | 391,27 | P | | 56067 | SPORANOX | sol 1x150ml/1.5gm | JAN | B | | | | | 274.9 | J02AX01 | flucytosin | p.o. | 10 | GM | 858,22 | P | | 275 | J02AC | triazolová antimykotika | parent. | U/P | | | | | --- | --- | --- | --- | --- | --- | --- | --- |
Terapeuticky: těžké, život ohrožující systémové mykózy.
Profylakticky: u imunokomprimovaných pacientů nebo pacientů připravovaných k transplantaci.
| 275.1 | J02AC01 | flukonazol | parent. | 0.2 | GM | 550,00 | U/P | | 58431 | DIFLAZON | inf 1x100ml/200mg | KRK | SLO | | | | | 46979 | FLUCONAZOL-SLOVAKOFARMA PRO INF | inf 1x100ml/200mg | SLO | SK | | | | | 275.2 | J02AX01 | flucytosin | parent. | 10 | GM | 2710,83 | U/P | | | | | | | | | | | 275.3 | J02AX04 | caspofungin s obsahem 50 mg v jedné ampulce | parent. | 1 | DF | 17259,00 | U/ATB | | | | | | | | | | | 275.4 | J02AX04 | caspofungin s obsahem 70 mg v jedné ampulce | parent. | 1 | DF | 24163,00 | U/ATB | | 276 | J04AB | antibiotika k léčbě tuberkulózy | p.o. | | | | | | --- | --- | --- | --- | --- | --- | --- | --- |
Léčbu rifabutinem ordinuje pneumolog nebo infekcionista: léčba tuberkulózy vyvolané atypickými mykobakteriemi.
| 276.1 | J04AB02 | rifampicin | p.o. | 0.6 | GM | 12,76 | | | 96780 | ARFICIN | cps 100x300mg | BLU | CHO | | | | | 276.2 | J04AB04 | rifabutin | p.o. | 0.15 | GM | 125,72 | P | | 277 | J04AB | antibiotika k léčbě tuberkulózy | parent. | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 277.1 | J04AB03 | rifamycin | parent. | 0.6 | GM | 244,40 | | | 277.2 | J04AB30 | kapreomycin | parent. | 1 | GM | 553,11 | | | 278 | J04AC | hydrazidy k léčbě tuberkulózy | p.o. | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 278.1 | J04AC01 | isoniazid | p.o. | 0.3 | GM | 2,04 | | | 03303 | NIDRAZID | tbl 250x100mg | LEX | CZ | | | | | 279 | J04AK | další léčiva k léčbě tuberkulózy | p.o. | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 279.1 | J04AK01 | pyrazinamid | p.o. | 1.5 | GM | 14,63 | | | 75508 | TISAMID | tbl 100x500mg | ORN | SF | | | | | 279.2 | J04AK02 | ethambutol | p.o. | 1.2 | GM | 12,22 | | | 03023 | SURAL | tbl 100x400mg | CHN | H | | | | | 280 | J04BA | chemoterapeutika k léčbě lepry | p.o. | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 280.1 | J04BA02 | dapson | p.o. | 50 | MG | 1,37 | | | 91888 | DISULONE 100 AU PROTOXAL.DE FER | tbl 100x100mg | LVN | F | | | | | 281 | J05A | antivirotika | p.o. | P | | | | | --- | --- | --- | --- | --- | --- | --- | --- |
Léčbu brivudinem, acyklovirem, famcyklovirem a valaciklovirem ordinuje infekcionista, onkolog, hematolog, gynekolog, dermatolog, klinický imunolog, neurolog a specialista pracující na transplantačních jednotkách:
- a) léčba iniciální fáze herpes genitalis u těhotných žen po 20. týdnu těhotenství,
- b) léčba herpes zoster a herpes genitalis u imunokomprimovaných pacientů (při cytostatické léčbě, léčbě imunosupresivy, léčbě kortikosteroidy, nebo u osob s prokázanou poruchou imunity, respektive u atopiků),
- c) léčba herpes zoster při lokalizaci v obličeji,
- d) profylaxe po alogenní transplantaci kostní dřeně.
Léčbu acyklovirem u pacientů s herpes zoster indikuje ošetřující lékař též odbornosti praktický lékař pro dospělé a praktický lékař pro děti a dorost.
Léčbu inosin pranobexem ordinuje alergolog nebo imunolog u pacientů s prokázanou poruchou imunity.
Léčbu antiretrovirovými léčivy (zidovudin, didanosin, zalcitabin, saquinavir, ritonavir, indavir, stavudin, efavirenz, nevirapin, nelfinavir, lamivudin a abacavir) indikuje infekcionista pracující v AIDS centrech.
Léčbu lamivudinem dále indikuje ošetřující lékař u chronické virové hepatitidy typu B.
Léčbu gancyklovirem ordinuje infekcionista, onkolog, hematolog a specialista pracující na transplantačních centrech:
- a) léčba a sekundární profylaxe závažných CMV infekcí u HIV/AIDS pacientů,
- b) profylaxe a léčba CMV infekcí u pacientů s allogenní a autologní transplantací kostní dřeně,
- c) profylaxe a léčba CMV infekcí u pacientů u orgánových transplantací.
| 281.1 | J05AB | brivudin | p.o. | 0.5 | GM | 458,88 | P |
|---|---|---|---|---|---|---|---|
| 281.2 | J05AB01 | acyklovir do 200 mg včetně | p.o. | 4 | GM | 320,00 | P |
| 84127 | HERPESIN 200 | tbl 25x200mg | LCM | CZ | |||
| 53608 | XOROX 200MG | tbl 25x200mg | KWI | A | |||
| 57068 | ACICLOVIR AL 200 | tbl 25x200mg | APA | D | |||
| 54213 | RANVIR 200 | tbl 25x200mg | RXG | IND | |||
| 54031 | PROVIRSAN | tbl 30x200mg | PMP | CZ | |||
| 281.3 | J05AB01 | acyklovir nad 200 mg | p.o. | 4 | GM | 265,00 | P |
| 84128 | HERPESIN 400 | tbl 25x400mg | LCM | CZ | |||
| 53610 | XOROX 400MG | tbl 60x400mg | KWI | A | |||
| 53611 | XOROX 800MG | tbl 35x800mg | KWI | A | |||
| 56079 | ACICLOVIR AL 400 | tbl 35x400mg | APA | D | |||
| 54216 | RANVIR 400 | tbl 20x400mg | RXG | IND | |||
| 281.4 | J05AB04 | ribavirin | p.o. | 1 | GM | 730,83 | X |
| 281.5 | J05AB06 | gancyklovir | p.o. | 3 | GM | 1960,07 | P |
| 59653 | CYMEVENE 250MG | cps 84x250mg | RPE | GB | |||
| 281.6 | J05AB09 | famcyklovir | p.o. | 0.75 | GM | 458,88 | P |
| 281.7 | J05AB11 | valacyklovir | p.o. | 3 | GM | 440,00 | P |
| 281.8 | J05AE01 | saquinavir | p.o. | 1,8 | GM | 504,14 | P |
| 59463 | FORTOVASE 200 MG | cps 180x200mg | HLR | D | |||
| 281.9 | J05AE02 | indinavir | p.o. | 2,4 | GM | 504,14 | P |
| 281.10 | J05AE03 | ritonavir | p.o. | 1,2 | GM | 504,14 | P |
| 281.11 | J05AE04 | nelfinavir | p.o. | 2,25 | GM | 504,14 | P |
| 281.12 | J05AE06 | lopinavir,ritonavir v kombinaci | p.o. | 6 | DF | 564,00 | P |
| 281.13 | J05AF01 | zidovudin | p.o. | 1.5 | GM | 685,28 | P |
| 281.14 | J05AF02 | didanosin | p.o. | 0.4 | GM | 236,43 | P |
| 281.15 | J05AF03 | zalcitabin | p.o. | 2.25 | MG | 235,25 | P |
| 66734 | HMD 0.75MG | tbl obd 100x0.75mg | HLR | CH | |||
| 281.16 | J05AF04 | stavudin | p.o. | 80 | MG | 302,07 | P |
| 53209 | ZERIT 40MG | cps 56x40mg | BMS | F | |||
| 53210 | ZERIT 40MG | cps 60x40mg | BMS | F | |||
| 281.17 | J05AF05 | lamivudin do 100 mg v jedné tabletě včetně respektive do 5 mg v jednom mililitru včetně | p.o. | 0,3 | GM | 292,03 | P |
| 02085 | ZEFFIX 100 MG | tbl obd 28x100mg | GOW | GB | |||
| 02086 | ZEFFIX 100 MG | tbl obd 84x100mg | GOW | GB | |||
| 02087 | ZEFFIX 5MG/ML | sol 1x240ml/1.2g | GWL | GB | |||
| 281.18 | J05AF05 | lamivudin nad 100 mg v jedné tabletě respektive nad 5 mg v jednom mililitru | p.o. | 0,3 | GM | 248,01 | P |
| 281.19 | J05AF06 | abacavir | p.o. | 600 | MG | 360,00 | P |
| 281.20 | J05AF30 | abacavir, lamivudin a zidovudin v kombinaci | p.o. | 2 | DF | 852,04 | P |
| 30158 | TRIZIVIR | por tbl flm 1x60 | GOW | GB | |||
| 281.21 | J05AF30 | jiné kombinace antiretrovirových virostatik (lamivudin a zidovudin) | p.o. | 2 | DF | 522,13 | P |
| 281.22 | J05AG01 | nevirapin | p.o. | 0,4 GM | 343,34 | P | |
| 57777 | VIRAMUNE | tbl 60x200mg | UUI | P | |||
| 281.23 | J05AG03 | efavirenz | p.o. | 0,6 | GM | 431,00 | P |
| 281.24 | J05AH01 | zanamivir | inhal. | 20 | MG | 130,00 | P |
Zanamivir je indikován pro léčbu influenzy A a B u pacientů, kteří z důvodů kontraindikace nebyli očkováni proti influenze nebo tam, kde očkování selhalo, u následujících skupin pacientů:
-
- děti starší 12 let s cystickou fibrózou, děti s onkologickým onemocněním na imunosupresivní léčbě
-
- dospělí se závažným chronickým plicním či kardiálním onemocněním na trvalé medikaci
-
- pacienti se závažným imunodeficitem, kde je po očkování nepravděpodobnost protilátkové odpovědi.
Z veřejného zdravotního pojištění je pro jednu terapeutickou kůru hrazeno jedno balení určené k pětidenní léčbě. Zanamivir u výše uvedených skupin ordinuje ošetřující lékař pouze v době chřipkové epidemie vyhlášené hlavním hygienikem.
| 281.25 | J05AX05 | inosin pranobex | p.o. | 1 | GM | 30,55 | P | | 88174 | ISOPRINOSINE | tbl 5x10(=50)x500mg | EWO | CH | | | | | 282 | J05AB | antivirotika ze skupiny nukloeosidů | parent. | U/P | | | | | --- | --- | --- | --- | --- | --- | --- | --- |
Léčbu brivudinem, acyklovirem, famcyklovirem a valaciklovirem ordinuje infekcionista, onkolog, hematolog, gynekolog, dermatolog, klinický imunolog, neurolog a specialista pracující na transplantačních jednotkách:
- a) léčba iniciální fáze herpes genitalis u těhotných žen po 20. týdnu těhotenství,
- b) léčba herpes zoster a herpes genitalis u imunokomprimovaných pacientů (při cytostatické léčbě, léčbě imunosupresivy, léčbě kortikosteroidy, nebo u osob s prokázanou poruchou imunity, respektive u atopiků),
- c) léčba herpes zoster při lokalizaci v obličeji,
- d) profylaxe po alogenní transplantaci kostní dřeně.
Léčbu inosin pranobexem ordinuje alergolog nebo imunolog u pacientů s prokázanou poruchou imunity.
Léčbu antiretrovirovými léčivy (zidovudin, didanosin, zalcitabin, saquinavir, ritonavir, indavir, stavudin, efavirenz, nevirapin, nelfinavir a lamivudin) indikuje infekcionista pracující v AIDS centrech.
Léčbu gancyklovirem ordinuje infekcionista, onkolog, hematolog a specialista pracující na transplantačních centrech:
- a) léčba a sekundární profylaxe závažných CMV infekcí u HIV/AIDS pacientů,
- b) profylaxe a léčba CMV infekcí u pacientů s allogenní a autologní transplantací kostní dřeně,
- c) profylaxe a léčba CMV infekcí u pacientů u orgánových transplantací.
| 282.1 | J05AB01 | acyklovir | parent. | 4 | GM | 1551,47 | U/P | | 53607 | XOROX 250MG | inf sic 5x250mg | KWI | A | | | | | 93260 | HERPESIN 250 | inf sic 10x250mg | PVL | CZ | | | | | 282.2 | J05AB06 | gancyklovir | parent. | 0.5 | GM | 1568,70 | U/P | | 02064 | CYMEVENE | inf sic 1x500mg | HLR | CH | | | | | 282.3 | J05AB12 | cidofovir | parent. | 375 | MG | 33556,50 | U/P | | 44745 | VISTIDE | inf 1x5ml 75mg/ml | PAU | B | | | | | 282.4 | J05AD01 | foskarnet | parent. | 6.5 | GM | 3006,25 | U/P | | | | | | | | | | | 282.5 | J05AF01 | zidovudin | parent. | 1 | GM | 2748,47 | U/P | | 283 | J06AA | imunitní séra | parent. | K/P | | | | | --- | --- | --- | --- | --- | --- | --- | --- |
Sérum proti stafylokokovým infekcím ordinuje lékař ke komplexní léčbě těžkých stafylokokových infekcí.
Sérum proti záškrtu ordinuje infekcionista nebo pediatr ke komplexní léčbě záškrtu.
Sérum proti hadímu jedu ordinuje lékař k léčbě uštknutí zmijí obecnou.
Sérum proti botulismu ordinuje lékař ke komplexní léčbě botulismu.
Sérum proti plynaté sněti ordinuje infekcionista nebo specialista chirurgických oborů k profylaxi a terapii klostridiových infekcí.
Sérum proti vzteklině ordinuje infekcionista k profylaxi nebo terapii vztekliny.
| 283.1 | J06AA | sérum proti stafylokokovým infekcím | parent. | plně | K/P | ||
|---|---|---|---|---|---|---|---|
| 283.2 | J06AA01 | sérum proti záškrtu | parent. | plně | K/P | ||
| 283.3 | J06AA03 | sérum proti hadímu jedu | parent. | plně | K/P | ||
| 83330 | IPSER EUROPE PASTEUR(ANTIVEN.) | inj 1x5ml | PMX | F | |||
| 283.4 | J06AA04 | sérum proti botulinu | parent. | plně | K/P | ||
| 01190 | BOSEA | inj 1x35ml | SVF | CZ | |||
| 283.5 | J06AA05 | sérum proti plynaté sněti | parent. | plně | K/P | ||
| 01195 | GASEA | inj 1x20ml/25ku | SVF | CZ | |||
| 283.6 | J06AA06 | sérum proti vzteklině | parent. | plně | K/P | ||
| 94015 | SERUM ANTIRAB.1000 U.I.PASTEUR | inj 1x5ml 200ut/ml | PMX | F | |||
| 284 | J06BA | imunoglobuliny, normální lidské | parent. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 284.1 | J06BA01 | imunoglobuliny, norm. lidské, k extravasální aplikaci do velikosti méně než 5 ml v jedné ampuli | parent. | 1 | DF | 175,50 | O |
| 57669 | PASTEUR.HUM. IMMUNOGL.GRIFOLS 16 | inj 1x2ml/320mg | GFO | E | |||
| 284.2 | J06BA01 | imunoglobuliny, norm. lidské, k extravasální aplikaci 5 ml a více v jedné ampuli | parent. | 1 | DF | 438,75 | O |
| 57670 | PASTEUR.HUM. IMMUNOGL.GRIFOLS 16 | inj 1x5ml/800mg | GFO | E | |||
| 284.3 | J06BA02 | imunoglobuliny normální lidské pro i.v. aplikaci | parent. | 1 GM | 956,88 | B | |
| 62553 | INTRAGLOBIN F PRO INFUS. | inf 1x50ml | BTP | D | |||
| 62554 | INTRAGLOBIN F PRO INFUS. | inf 1x100ml | BTP | D | |||
| 62555 | INTRAGLOBIN F PRO INFUS. | inf 1x200ml | BTP | D | |||
| 284.4 | J06BA02 | imunoglobuliny normální lidské pro i.v. aplikaci (s obsahem IgM) | parent. | 1 | GM | 1955,16 | U |
| 284.5 | J06BA | imunoglobuliny, norm. lidské ( k extravasální aplikaci), kombinace s histaminem | parent. | 1 | DF | 89,40 | O |
| 87736 | HISTAGLOBIN | inj sic 3x12mg+sol. | BBL | CH | |||
| 285 | J06BB | specifické imunoglobuliny | parent. | K | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
Léčbu imunoglobuliny proti nešťovicím a pásovému oparu ordinuje infekcionista, onkolog, hematolog a pediatr:
- a) neočkované těhotné ženy,
- b) novorozenec po kontaktu s varicellou,
- c) imunokomprimovaný pacient po kontaktu s varicellou,
- d) varicelózní primární pneumonitis.
Léčbu imunoglobulinem proti cytomegalovirové infekci ordinuje infekcionista, onkolog, hematolog nebo pediatr:
- a) novorozenec s prokázanou cytomegalovirovou infekcí,
- b) generalizovaná cytomegalovirová infekce u imunokomprimovaných pacientů,
- c) profylaxe cytomegalovirových infekcí u transplantovaných pacientů při pozitivitě dárce nebo příjemce. Imunoglobulin proti cytomegalovirové infekci je hrazen dle symbolu U.
Imunoglobulin proti tetanu je hrazen dle symbolu B.
| 285.1 | J06BB12 | protiencefalický globulin | parent. | 1 | ML | 300,65 | K | | 95084 | FSME-BULIN I.M. | inj 1x5ml | IMM | A | | | | | 95082 | FSME-BULIN I.M. | inj 1x1ml | IMM | A | | | | | 95083 | FSME-BULIN I.M. | inj 1x2ml | IMM | A | | | | | 285.2 | J06BB01 | anti-d (rh) imunoglobulin (do 100 rg v jedné ampuli včetně) | parent. | 250 | RG | 1407,96 | K | | | | | | | | | | | 285.3 | J06BB01 | anti-d (rh) imunoglobulin (nad 100 rg v jedné ampuli) | parent. | 250 RG | 1320,40 | K | | | 91307 | PARTOBULIN-INJECT I.M. | inj 1x1ml/250rg | OIH | A | | | | | 285.4 | J06BB02 | imunoglobulin proti tetanu | parent. | | plně | B | | | 44669 | PASTEURISED HUM.ANTITET.IG.GRIF | inj sic 1x500ut+2ml | GFO | E | | | | | 83607 | TETABULIN | inj 250ut/ml | IMM | A | | | | | 57804 | PASTEURISED HUM.ANTITET.IG.GRIF | inj 1x1ml/250ut-str | GFO | E | | | | | 57805 | PASTEURISED HUM.ANTITET.IG.GRIF | inj 1x2ml/500ut-str | GFO | E | | | | | 44668 | PASTEURISED HUM.ANTITET.IG.GRIF | inj sic 1x250ut+2ml | GFO | E | | | | | 285.5 | J06BB03 | imunoglobulin proti neštovicím a pásovému oparu | parent. | 1 | KU | 32724,00 | K/P | | 97896 | VARITECT(R) | inj 1x50ml | BTP | D | | | | | 97894 | VARITECT(R) | inj 1x5ml | BTP | D | | | | | 97895 | VARITECT(R) | inj 1x20ml | BTP | D | | | | | 285.6 | J06BB04 | imunoglobulin proti hepatitidě B | parent. | | | plně | K | | 57419 | PASTEURISED HUM.ANTIHEP.B GFO | inj 1x3ml/600ut | GFO | E | | | | | 57420 | PASTEURISED HUM.ANTIHEP.B GFO | inj 1x5ml/1000ut | GFO | E | | | | | 97897 | HEPATECT(R) | inj 1x2ml | BTP | D | | | | | 97898 | HEPATECT(R) | inj 1x10ml | BTP | D | | | | | 285.7 | J06BB05 | imunoglobulin proti rabies | parent. | | | plně | K/P | | 46731 | IMOGAM RABIES PASTEURIZED | inj 1x10ml/1500ut | AVS | F | | | | | 53163 | IMOGAM RABIES PASTEURIZED | inj 1x2ml/300ut | AVS | F | | | | | 285.8 | J06BB09 | imunoglobulin proti cytomegalovirové infekci | parent. | 1 | GM | 4817,20 | U/P | | 94864 | CYTOTECT | inf 1x50ml 100mg/ml | BTP | D | | | | | 94862 | CYTOTECT | inj 1x10ml 100mg/ml | BTP | D | | | | | 94863 | CYTOTECT | inj 1x20ml 100mg/ml | BTP | D | | | | | 285.9 | J06BB16 | palivizumab do 50 mg v jedné ampuli včetně | parent | 1 | DF | 27.645 | X | | 02106 | SYNAGIS 50MG | inj sic 1x50mg+sol | ABB | I | | | | | 285.10 | J06BB16 | palivizumab nad 50 mg v jedné ampuli | parent. | 1 | DF | 45.568,00 | X | | 02143 | SYNAGIS 100MG | inj sic 1x100mg+sol | ABB | I | | | | | 286 | J07AM | očkovací látky proti tetanu | parent. | K | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 286.1 | J07AM01 | tetanový toxoid | parent. | | | plně | K | | 83444 | TETAVAX | inj 20x0.5ml-strik. | PMX | F | | | | | 83622 | ALTEANA | inj 10x0.5ml | SVF | CZ | | | | | 83443 | TETAVAX | inj 1x0.5ml-strik. | PMX | F | | | | | 83526 | TETAVAX | inj 10x10ml | PMX | F | | | | | 83447 | TETAVAX | inj 10x20ml | PMX | F | | | | | 83445 | TETAVAX | inj 1x10ml | PMX | F | | | | | 83525 | TETAVAX | inj 20x0.5ml-ampule | PMX | F | | | | | 287 | J07AN | očkovací látky proti tuberkulóze | parent. | O | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 287.1 | J07AN01 | tuberkulosa, živé atenuované mykobakterium | parent. | 1 | DF | 229,40 | H | | 76028 | LYOPHILIZED B.C.G.VACCINE | lyo 10x20davek+sol. | PMX | F | | | | | 76027 | LYOPHILIZED B.C.G.VACCINE | lyo 10x10davek+sol. | PMX | F | | | | | 58227 | BCG VACCINE SSI | inj sic 10x10dav+so | SST | DK | | | | | 58228 | BCG VACCINE SSI | inj sic 10x20dav+so | SST | DK | | | | | 76189 | BCG-VACCINE 500 BEHRING | inj sic 50x0.1ml+so | CBG | D | | | | | 66855 | BCG-VACCINE BEHRING | inj sic 1x0.1ml+sol | CBG | D | | | | | 288 | J07AX | jiné bakteriální očkovací látky | parent. | K | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 288.1 | J07AX | jiné bakteriální vakcíny (protistafyloko- ková vakcína) | parent. | | | plně | K | | 94269 | POLYSTAFANA | inj 10x0.5ml | SVF | CZ | | | | | 288.2 | J07AX jiné bakteriální vakcíny (směs bakterinů) | parent. | 1 | DF | 26,15 | K | | | | | | | | | | | | 288.3 | J07AX | jiné bakteriální vakcíny (protipseudo-monádová vakcína) | parent. | 1 | DF | 206,02 | O | | | | | | | | | | | 288.4 | J07AX | jiné bakteriální vakcíny (uropatogenní vakcína) | parent. | 1 | DF | 280,47 | O |
Vybrané vakcíny se podávají u splenektomovaných pacientů po nebo před výkonem a u pacientů po transplantaci krvetvorných buněk.
Meningokokus, bivalentni polysacharidový antigen se podává po nebo před výkonem u splenektomovaných pacientů.
| 288.5 | J07AG01 | hemofilus influenze B, čistěný purifikovaný antigen | parent. | 1 DF | 212,30 | O/P | |
|---|---|---|---|---|---|---|---|
| 288.6 | J07AG51 | hemofilus influenze B, kombinace s toxoidy | parent. | 1 | DF | 212,30 | O/P |
| 288.7 | J07AL01 | pneumokoková vakcína | parent. | 1 | DF | 208,70 | O/P |
| 288.8 | J07AM51 | tetanový anatoxin, kombinace s anatoxinem záškrtu | parent. | 1 | DF | 11,67 | O/P |
| 01221 | ALDITEANA SEVAC | inj 10x0.5ml | SEV | CZ | |||
| 288.9 | J07BB02 | chřipka, čištěný antigen | parent. | 1 | DF | 188,90 | O/P |
| 12877 | INFLUVAC | injsus10x0.5ml/1dáv | SOO | NL | |||
| 83429 | VAXIGRIP | inj 1x0.5ml | PMX | F | |||
| 49482 | INFLUVAC | injsus1xÖ.5ml/dav. | SOO | NL | |||
| 288.10 | J07BF03 | dětská obrna, trivalentní, inaktivovaný celý virus | parent. | 1 | DF | 95,30 | O/P |
| 288.11 | J07BJ01 | zarděnky, živý oslabený virus | parent. | 1 | DF | 74,00 | O/P |
| 88548 | ERVEVAX RUBELLA VACCINE S.C. | inj sic 10dav.+solv | SKX | B | |||
| 88549 | ERVEVAX RUBELLA VACCINE | inj pso Iqf 50dÁv. | SKX | B | |||
| 288.12 | J07AH03 | meningokokus, bivalentní čištěný polysacharidový antigen | parent. | 1 | DF | 115,10 | O/P |
| 76063 | MENINGOCOCCAL POLYS.A+C VACCINE | inj 1x1dav.+strik. | PMX | F | |||
| 289 | J07BG | očkovací látky proti vzteklině | parent. | K | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 289.1 | J07BG01 | inaktivovaný celý virus vztekliny | parent. | plně | K | ||
| 75379 | RABIPUR | inj sic 1x2.5ut | CBG | D | |||
| 90996 | RABIPUR | inj sic 5x2.5ut | CBG | D | |||
| 93706 | VERORAB | inj sic 1dav.+0.5ml | PMX | F | |||
| 290 | L01AA | alkylační cytostatika | p.o. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 290.1 | L01AA01 | cyklofosfamid | p.o. | 0.1 | GM | 5,52 | |
| 94174 | CYCLOPHOSPHAMIDE ORION | tbl obd 50x50mg | ONA | SF | |||
| 290.2 | L01AA02 | chlorambucil (do 2 mg v jedné tabletě včetně) | p.o. | 1 | MG | 4,50 | |
| 11244 | LEUKERAN | tbl obd 25x2mg | GWE | GB | |||
| 290.3 | L01AA02 | chlorambucil (nad 2 mg v jedné tabletě) | p.o. | 1 | MG | 3,72 | |
| 290.4 | L01AA03 | melfalan (do 2 mg v jedné tabletě včetně) | p.o. | 1 | MG | 4,30 | |
| 32213 | ALKERAN 2 MG | por tbl obd 25x2mg | GOK | GB | |||
| 290.5 | L01AA03 | melfalan (nad 2 mg v jedné tabletě) | p.o. | 1 | MG | 2,88 | |
| 290.6 | L01AA08 | prednimustin | p.o. | 1 | MG | 3,62 | |
| 290.7 | L01AX03 | temozolomid | p. o. | 370 | MG | 15998,00 | X |
| 66109 | TEMODAL 20MG | cps 5x20mg | SCH | B | |||
| 66106 | TEMODAL 250MG | cps 5x250mg | SCH | B | |||
| 66104 | TEMODAL 100MG | cps 5x100mg | SCH | B | |||
| 291 | L01AA | alkylační cytostatika | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 291.1 | L01AA01 | cyklofosfamid | parent. | 10 | MG | 3,52 | B |
| 10777 | CYTOXAN 1 G | inj sic 6x1gm | BMS | POR | |||
| 10776 | CYTOXAN 500 MG | inj sic 12x500mg | BMS | POR | |||
| 70442 | CYTOXAN | inj sic 12x500mg | BMS | USA | |||
| 70441 | CYTOXAN | inj sic 12x200mg | BMS | USA | |||
| 70443 | CYTOXAN | inj sic 6x1gm | BMS | USA | |||
| 291.2 | L01AA03 | melfalan | parent. | 1 | MG | 12,61 | B/ONK,HEM |
| 32508 | ALKERAN | inj pso Iqf 50mg | GOK | GB | |||
| 32507 | ALKERAN | inj pso Iqf 50mg | GXW | I | |||
| 291.3 | L01AA05 | chlormethin | parent. | 1 | MG | 34,22 | B/ONK,HEM |
| 291.4 | L01AA06 | ifosfamid (do 500 mg v jedné ampuli včetně) | parent. | 1 | MG | 1,42 | B/ONK,HEM |
| 291.5 | L01AA06 | ifosfamid (nad 500 mg v jedné ampuli) | parent. | 1 | MG | 1,32 | B/ONK,HEM |
| 70469 | HOLOXAN 2GM | inj sic 1x2gm | ASD | D | |||
| 291.6 | L01AC01 | thiotepa | parent. | 1 | MG | 21,31 | B/ONK,HEM |
| 291.7 | L01AX04 | dakarbazin | parent. | 10 | MG | 7,90 | B/ONK,HEM |
| 88441 | DACARBAZIN LACHEMA 200 | inj sic 10x200mg | LCM | CZ | |||
| 88561 | DACARBAZIN LACHEMA 500 | inj sic 5x500mg | LCM | CZ | |||
| 88440 | DACARBAZIN LACHEMA 100 | inj sic 10x100mg | LCM | CZ | |||
| 88560 | DACARBAZIN LACHEMA 500 | inj sic 1x500mg | LCM | CZ | |||
| 89999 | DACARBAZIN LACHEMA 1000 | inj sic 1x1000mg | LCM | CZ | |||
| 90000 | DACARBAZIN LACHEMA 1000 | inj sic 5x1000mg | LCM | CZ | |||
| 292 | L01AB | alkylsulfaty | p.o. | L/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 292.1 | L01AB01 | busulfán (do 0,5 mg v jedné tabletě včetně) | p.o. | 1 | MG | 14,86 | L/ONK,HEM |
| 292.2 | L01AB01 | busulfán (nad 0,5 mg v jedné tabletě) | p.o. | 1 | MG | 4,89 | L/ONK,HEM |
| 293 | L01AD | nitrosomočoviny | p.o. | L/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 293.1 | L01AD02 | lomustin (do 10 mg v jedné tabletě včetně) | p.o. | 1 MG | 5,72 | L/ONK,HEM | |
| 293.2 | L01AD02 | lomustin (nad 10 do 40 mg v jedné tabletě včetně) | p.o. | 1 MG | 5,63 | L/ONK,HEM | |
| 03735 | CEENU LOMUSTINE(CCNU) COMBI | cps 6 | BMS | USA | |||
| 293.3 | L01AD02 | lomustin (nad 40 mg v jedné tabletě) | p.o. | 1 | MG | 4,39 | L/ONK,HEM |
| 60272 | CEENU LOMUSTINE (CCNU) 100MG | cps 20x100mg | BMS | USA | |||
| 294 | L01AD | nitrosomočoviny | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 294.1 | L01AD01 | karmustin | parent. | 1 | MG | 9,92 | B/ONK,HEM |
| 53666 | BICNU(STERILE CARMUSTINE/BCNU/) | inj sic 1x100mg+sol | BMS | I | |||
| 83482 | BICNU(CARMUSTINE FOR I.V.-BCNU) | inj sic 1x100mg+3ml | BMS | USA | |||
| 294.2 | L01AD04 | streptozocin | parent. | 10 | MG | 14,81 | B/ONK,HEM |
| 294.3 | L01AD05 | fotemustin | parent. | 1 | MG | 94,48 | B/P |
Fotemustin - léčba generalizovaného maligního melanomu. Léčbu ordinuje onkolog pouze na pracovištích se speciálním smluvním vztahem se zdravotními pojišťovnami.
| 295 | L01BA | antimetabolity ze skupiny analog kyseliny listové | p.o. | ||||
|---|---|---|---|---|---|---|---|
| 295.1 | L01BA01 | metotrexát | p.o. | 1 | MG | 1,52 | |
| 91922 | METHOTREXAT LACHEMA 10 | tbl 100x10mg | LCM | CZ | |||
| 91065 | METHOTREXAT LACHEMA 2.5 | tbl 100x2.5mg | LCM | CZ | |||
| 296 | L01BA | antimetabolity ze skupiny analog kyseliny listové | parent. | B | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 296.1 | L01BA01 | metotrexát (do 5 mg v jedné ampuli včetně) | parent. | 1 | MG | 9,09 | B |
| 91025 | METHOTREXAT LACHEMA 5 | inj 10x2ml/5mg | LCM | CZ | |||
| 12787 | METHOTREXATE-TEVA 2.5MG/ML | inj 5x2ml/5mg | AIC | IL | |||
| 10827 | METHOTREXATE-TEVA 2.5MG/ML | inj 5x2ml/5mg | PHM | NL | |||
| 296.2 | L01BA01 | metotrexát (nad 5 do 500 mg v jedné ampuli včetně) | parent. | 1 | MG | 3,23 | B |
| 12788 | METHOTREXATE-TEVA 25MG/ML | inj 1x2ml/50mg | AIC | IL | |||
| 93963 | METHOTREXAT LACHEMA 20 | inj 10x2ml/20mg | LCM | CZ | |||
| 87564 | METHOTREXAT LACHEMA 50 | inj sic 10x50mg | LCM | CZ | |||
| 11193 | METHOTREXATE-TEVA 25MG/ML | inj 1x4ml/100mg-lah | PHM | NL | |||
| 87761 | METHOTREXAT LACHEMA 500 | inj sic 10x500mg | LCM | CZ | |||
| 93964 | METHOTREXAT LACHEMA 50 | inj 10x5ml/50mg | LCM | CZ | |||
| 12789 | METHOTREXATE-TEVA 25MG/ML | inj 1x4ml/100mg | AIC | IL | |||
| 12790 | METHOTREXATE-TEVA 25MG/ML | inj 1x8ml/200mg | AIC | IL | |||
| 11192 | METHOTREXATE-TEVA 25MG/ML | i inj 5x2ml/50mg-amp. | PHM | NL | |||
| 12791 | METHOTREXATE-TEVA 25MG/ML | inj 1x20ml/500mg | AIC | IL | |||
| 12792 | METHOTREXATE-TEVA 25MG/ML | inj 5x2ml/50mg | AIC | IL | |||
| 11191 | METHOTREXATE-TEVA 25MG/ML | inj 1x2ml/50mg-lahv | PHM | NL | |||
| 64784 | METHOTREXAT EBEWE | inf 1x5ml/500mg | EBW | A | |||
| 11194 | METHOTREXATE-TEVA 25MG/ML | inj 1x8ml/200mg-lah | PHM | NL | |||
| 83484 | METHOTREXAT LEDERLE | inf 1x20ml/500mg | LED | D | |||
| 11195 | METHOTREXATE-TEVA 25MG/ML | inj 1x20ml/500mg-la | PHM | NL | |||
| 296.3 | L01BA01 | metotrexát (nad 500 mg v jedné ampuli) | parent. | 10 | MG | 4,89 | B |
| 93965 | METHOTREXAT LACHEMA 1000 | inj 10x20ml/1000mg | LCM | CZ | |||
| 296.4 | L01BA03 | raltitrexed | parent. | 1 | DF | 7498,20 | X |
| 297 | L01BB | antimetabolity ze skupiny analog purinů | p.o. | L/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 297.1 | L01BB02 | merkaptopurin | p.o. | 10 | MG | 6,21 | L/ONK,HEM |
| 94241 | PURI-NETHOL | tbl 25x50mg | BWE | GB | |||
| 297.2 | L01BB03 | tioguanin | p.o. | 10 | MG | 9,34 | L/ONK,HEM |
| 297.3 | L01BB05 | fludarabin | p.o. | 1 | MG | 87,20 | L/ONK,HEM |
| 58898 | FLUDARA | tbl obd 20x10mg | SAG | D | |||
| 58897 | FLUDARA | tbl obd 15x10mg | SAG | D | |||
| 298 | L01BB | antimetabolity ze skupiny analog purinů | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 298.1 | L01BB04 | cladribin | parent. | 1 | MG | 884,61 | B/ONK,HEM |
| 298.2 | L01BB05 | fludarabin | parent. | 1 | MG | 126,51 | B/ONK,HEM |
| 59058 | FLUDARA | inj sic 5x50mg | SHI | I | |||
| 77008 | FLUDARA I.V. | inj sic 5x50mg | SAG | D | |||
| 299 | L01BC | antimetabolity ze skupiny analog pyrimidinu | p.o. | L/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 299.1 | L01BC | azaribin | p.o. | 1 | MG | 8,50 | L/ONK,HEM |
| 299.2 | L01BC02 | fluorouracil | p.o. | 10 | MG | 1,47 | L/ONK,HEM |
| 299.3 | L01BC03 | tegafur | p.o. | 10 | MG | 1,48 | L/ONK,HEM |
| 10407 | FTORAFUR | cps 100x400mg | GRX | LV | |||
| 299.4 | L01BC06 | capecitabin do 150 mg v jedné tabletě včetně | p.o. | 1 | DF | 38,05 | X |
| 30397 | XELODA 150 MG | por tbl flm 60x150mg | HLR | D | |||
| 299.5 | L01BC06 | capecitabin nad 150 mg v jedné tabletě | p.o. | 1 | DF | 126,19 | X |
| 30402 | XELODA 500 MG | por tbl flm 120x500mg | HLR | D | |||
| 300 | L01BC | antimetabolity ze skupiny analog pyrimidinu | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 300.1 | L01BC01 | cytarabin (do 100 mg v jedné ampuli včetně) | parent. | 1 | MG | 1,27 | B/ONK,HEM |
| 99484 | ALEXAN (LAHVICKY) | inj 30x2ml/40mg | MAC | D | |||
| 99483 | ALEXAN (LAHVICKY) | inj 10x5ml/100mg | MAC | D | |||
| 300.2 | L01BC01 | cytarabin (nad 100 mg v jedné ampuli) | parent. | 1 | MG | 1,03 | B/ONK,HEM |
| 96990 | ALEXAN (LAHVICKY) | inj 1x20ml/1000mg | MAC | D | |||
| 300.3 | L01BC02 | fluorouracil | parent. | 10 | MG | 2,72 | B/ONK,HEM |
| 11171 | FLUOROURACIL-TEVA | inj 1x5ml/250mg | PHM | NL | |||
| 56055 | 5-FLUOROURACIL EBEWE | inj 1x5ml/250mg | EBW | A | |||
| 32752 | FLUORO-URACIL ICN | injsoi 5x20ml/1gm | SOC | CH | |||
| 58240 | FLUORO-URACIL ICN | inj sol 5x5ml/250mg | SOC | CH | |||
| 11393 | LA-FU 50 MG/ML | inj 1x10ml/500mg | PVL | CZ | |||
| 12666 | 5-FLUOROURACIL EBEWE | inj 1x20ml/1000mg | EBW | A | |||
| 11101 | LA-FU 50 MG/ML | inj 5x20ml/1000mg | PVL | CZ | |||
| 32751 | FLUORO-URACIL ICN | injsol 5x10ml/500mg | SOC | CH | |||
| 11117 | LA-FU 50 MG/ML | inj 1x20ml/1000mg | PVL | CZ | |||
| 11100 | LA-FU 50 MG/ML | inj 10x5ml/250mg | PVL | CZ | |||
| 11175 | FLUOROURACIL-TEVA | inj 1x20ml/1000mg | PHM | NL | |||
| 57650 | LA-FU 500 | inj 1x10ml/500mg | LCM | CZ | |||
| 32761 | FLUOROURACIL-TEVA | inj sol 1x100ml/5gm | PHM | NL | |||
| 12665 | 5-FLUOROURACIL EBEWE | inj 1x10ml/500mg | EBW | A | |||
| 32750 | FLUORO-URACIL ICN | injsol 10x5ml/250mg | SOC | CH | |||
| 32753 | FLUORO-URACIL ICN | injsol 1x100ml/5gm | SOC | CH | |||
| 11173 | FLUOROURACIL-TEVA | inj 1x10ml/500mg | PHM | NL | |||
| 12667 | 5-FLUOROURACIL EBEWE | inj 1x100ml/5000mg | EBW | A | |||
| 11394 | LA-FU 50 MG/ML | inj 10x10ml/500mg | PVL | CZ | |||
| 300.4 | L01BC03 | tegafur | parent. | 10 | MG | 2,83 | B/ONK,HEM |
| 300.5 | L01BC05 | gemcitabin | parent. | 1 | MG | 5,87 | X |
| 301 | L01CA | vinka alkaloidy a jejich deriváty | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 301.1 | L01CA01 | vinblastin | parent. | 1 | MG | 26,54 | B/ONK,HEM |
| 301.2 | L01CA02 | vinkristin | parent. | 1 | MG | 182,10 | B/ONK,HEM |
| 12772 | VINCRISTINE-TEVA | inj sic 1x1mg+solv. | AIC | IL | |||
| 11421 | VINCRISTINE-TEVA | inj 1x2ml/2mg | PHM | NL | |||
| 12773 | VINCRISTINE TEVA | inj 1x1ml/1mg | AIC | IL | |||
| 47220 | VINCRISTINE TEVA | inj 1x2ml/2mg | AIC | IL | |||
| 10707 | VINCRISTINE-TEVA | inj sic 1x1mg+solv. | PHM | NL | |||
| 47221 | VINCRISTINE TEVA | inj 1x5ml/5mg | AIC | IL | |||
| 11422 | VINCRISTINE-TEVA | inj 1x5ml/5mg | PHM | NL | |||
| 11420 | VINCRISTINE-TEVA | inj 1x1ml/1mg | PHM | NL | |||
| 301.3 | L01CA04 | vinorelbin | parent. | 1 | MG | 108,27 | X |
| 302 | L01CB | podofylotoxinové deriváty | p.o. | L/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 302.1 | L01CB01 | etoposid | p.o. | 1 | MG | 3,05 | L/ONK,HEM |
| 86417 | VEPESID | cps 10x100mg | BMS | D | |||
| 86416 | VEPESID | cps 20x50mg | BMS | D | |||
| 86710 | VEPESID | cps 10x100mg | BMS | I | |||
| 97401 | VEPESID | cps 20x50mg | BMS | I | |||
| 93696 | LASTET | cps 40x25mg | NKU | J | |||
| 93698 | LASTET | cps 10x100mg | NKU | J | |||
| 93697 | LASTET | cps 20x50mg | NKU | J | |||
| 303 | L01CB | podofylotoxinové deriváty | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 303.1 | L01CB01 | etoposid | parent. | 1 | MG | 3,02 | B/ONK,HEM |
| 86709 | VEPESID | inf cnc10x5ml/100mg | BMS | I | |||
| 86418 | VEPESID | inj 10x5ml/100mg | BMS | D | |||
| 303.2 | L01CB02 | teniposid | parent. | 1 | MG | 6,06 | B/ONK,HEM |
| 304 | L01CD | taxany | parent. | X | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 304.1 | L01CD01 | paclitaxel | parent. | 1 | MG | 140,25 | X |
| 05952 | PAXENE | inf cnc16.7ml/100mg | IVX | CZ | |||
| 05953 | PAXENE | inf cnc 50ml/300mg | IVX | CZ | |||
| 45154 | PAXENE | inf cnc 1x5ml/30mg | IVX | CZ | |||
| 45155 | PAXENE | inf cnc 25ml/150mg | IVX | CZ | |||
| 304.2 | L01CD02 | docetaxel | parent. | 1 | MG | 245,83 | X |
| 305 | L01DA | aktinomyciny | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 305.1 | L01DA01 | daktinomycin | parent. | 1 | MG | 664,85 | B/ONK,HEM |
| 306 | L01DB | antracykliny a jejich deriváty | p.o. | X | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 306.1 | L01DB06 | idarubicin | p.o. | 1 | MG | 274,70 | X |
| 78812 | ZAVEDOS 5MG | cps 1x5mg | FAR | I | |||
| 78813 | ZAVEDOS 10MG | cps 1x10mg | FAR | I | |||
| 78814 | ZAVEDOS 25MG | cps 1x25mg | FAR | I | |||
| 307 | L01DB | antracykliny a jejich deriváty | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 307.1 | L01DB01 | doxorubicin (do 40 mg včetně v jedné ampuli) | parent. 1 MG | 33,58 | B/ONK,HEM | ||
| 30949 | DOXORUBICIN LACHEMA 10 | inj plv sol 1x10mg | PVL | CZ | |||
| 12663 | DOXORUBICIN EBEWE 10MG | inj 1x5ml/10mg | EBW | A | |||
| 307.2 | L01DB01 | doxorubicin (nad 40 mg v jedné ampuli) | parent. | 1 | MG | 32,18 | B/ONK,HEM |
| 30950 | DOXORUBICIN LACHEMA 50 | inj plv sol 1x50mg | PVL | CZ | |||
| 12664 | DOXORUBICIN EBEWE 50MG | inj 1x25ml/50mg | EBW | A | |||
| 307.3 | L01DB02 | daunorubicin | parent. | 1 | MG | 19,21 | B/ONK,HEM |
| 307.4 | L01DB03 | epirubicin | parent. | 1 | MG | 40,08 | B/ONK,HEM |
| 307.5 | L01DB04 | aklarubicin | parent. | 1 | MG | 19,21 | B/ONK,HEM |
| 307.6 | L01DB05 | zorubicin | parent. | 1 | MG | 19,21 | B/ONK,HEM |
| 307.7 | L01DB06 | idarubicin | parent. | 1 | MG | 753,57 | B/ONK,HEM |
| 307.8 | L01DB07 | mitoxantron | parent. | 1 | MG | 53,96 | B/ONK,HEM |
| 54033 | REFADOR | inj cnc 1x15ml/30mg | PVL | CZ | |||
| 308 | L01DC | ostatní cytotoxická antibiotika | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 308.1 | L01DC01 | bleomycin | parent. | 1 | MG | 66,36 | B/ONK,HEM |
| 03404 | BLEOCIN | inj 1x15mg | NKU | J | |||
| 308.2 | L01DC03 | mitomycin (do 2 mg v jedné ampuli včetně) | parent. | 1 | MG | 76,25 | B/ONK,HEM |
| 308.3 | L01DC03 | mitomycin (nad 2 mg v jedné ampuli) | parent. | 1 | MG | 70,36 | B/ONK,HEM |
| 309 | L01XA | platinová cytostatika | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 309.1 | L01XA01 | cisplatina | parent. | 1 | MG | 8,21 | B/ONK,HEM |
| 96453 | PLATIDIAM | inj 10x10mg/20ml | LCM | CZ | |||
| 92302 | CISPLATIN EBEWE | inf 1x100ml/50mg | EBW | A | |||
| 96454 | PLATIDIAM | inj 5x25mg/50ml | LCM | CZ | |||
| 96455 | PLATIDIAM | inj 1x50mg/100ml | LCM | CZ | |||
| 309.2 | L01XA02 | karboplatina (do 50 mg v jedné ampuli včetně) | parent. 1 | MG | 6,70 | B/ONK,HEM | |
| 75010 | CYCLOPLATIN 50 | inf cnc sol 1x5ml | PVL | CZ | |||
| 90777 | CYCLOPLATIN 50 | inf plv sol 10x50mg | PVL | CZ | |||
| 309.3 | L01XA02 | karboplatina (nad 50 mg v jedné ampuli) | parent. | 1 | MG | 3,86 | B/ONK,HEM |
| 10830 | CARBOPLATIN-TEVA | inj 1x45ml/450mg | PHM | NL | |||
| 93665 | CYCLOPLATIN 200 | inf plv sol 5x200mg | PVL | CZ | |||
| 310 | L01XB | methylhydrazinová cytostatika | p.o. | L/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 310.1 | L01XB01 | prokarbazin | p.o. | 10 | MG | 2,44 | L/ONK,HEM |
| 311 | L01XX | ostatní cytostatika | p.o. | L/ONK,HEM,URN | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 311.1 | L01XX05 | hydroxymočovina | p.o. | 0.1 | GM | 2,23 | L/ONK,HEM,URN |
| 57345 | LITARIL | CPS 100x500mg | BMS | I | |||
| 311.2 | L01XX11 | estramustin | p.o. | 10 | MG | 3,91 | L/ONK,HEM,URN |
| 58742 | ESTRACYT | cps 100x140mg | PUA | I | |||
| 08921 | ESTRACYT | cps 100x140mg | PHA | S | |||
| 311.3 | L01XX14 | tretinoin | p.o. | 10 | MG | 101,68 | L/ONK,HEM,URN |
| 84009 | VESANOID | cps 100x10mg | HLR | CH | |||
| 311.4 | L01XX28 | imatinib | p.o. | 400 | MG | 2672,95 | X |
| 40199 | GLIVEC 100MG | cps 120x100mg | NPF | CH | |||
| 312 | L01XX | ostatní cytostatika | parent. | B/ONK,HEM | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 312.1 | L01XC02 | rituximab | parent. | 10 | MG | 1336,46 | Z |
| 59839 | MABTHERA 100MG | inf 2x10ml/100mg | HLR | D | |||
| 46130 | MABTHERA 500MG | inf 1x50ml/500mg | HLR | D | |||
| 312.2 | L01XC03 | trastuzumab | parent. | 1 | DF | 26200,00 | X |
| 312.3 | L01XD02 | verteporfin | parent. | 15 | MG | 44000,00 | X |
| 312.4 | L01XX01 | amsakrin | parent. | 1 | MG | 25,80 | B/ONK,HEM |
| 312.5 | L01XX02 | asparagináza | parent. | 1 | MG | 2784,54 | B/P |
Léčbu L-asparaginázou ordinuje onkolog nebo hematolog. Revizní lékař pojišťovny může na základě žádosti lékaře povolit plnou úhradu ekonomicky náročnějších přípravků obsahujících L-asparaginázu v případě, že se jedná o podání dětem do 18 let věku, nebo že se jedná o opakované podání starším osobám, případně u pacientů s alergickou anamnézou.
| 58319 | KIDROLASE | inj sic 10x10ku | THN | B | | | | | 94058 | ERWINASE | inj sic 20x10ku | POT | GB | | | | | 312.6 | L01XX11 | estramustin | parent. | 1 | MG | 1,03 | B/ONK,HEM,URN | | | | | | | | | | | 312.7 | L01XX17 | topotekan | parent. | 1 | MG | 3066,38 | X | | | | | | | | | | | 312.8 | L01XX19 | irinotekan | parent. | 1 | MG | 76,68 | X | | 56005 | CAMPTO 40MG/2ML | sol inf 1x2ml/40mg | RDG | GB | | | | | 312.9 | L01XX09 | miltefosin | lok. | 60 | MG | 9,78 | | | 313 | L02AA | estrogeny | p.o. | L/ONK,HEM,URN,GYN, SEX | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 313.1 | L02AA01 | diethylstilbestrol | p.o. | 10 | MG | 3,32 | L/ONK,HEM,URN GYN,SEX | | 313.2 | L02AA03 | ethinylestradiol | p.o. | 1 | MG | 4,06 | L/ONK,HEM,URN GYN,SEX | | | | | | | | | | | 313.3 | L02AA04 | fosfestrol | p.o. | 0.1 | GM | 3,32 | L/ONK,HEM,URN GYN,SEX | | 314 | L02AA | estrogeny | parent. | B/ONK,HEM,URN,SEX | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 314.1 | L02AA01 | diethylstilbestrol | parent. | 10 | MG | 6,55 | B/ONK,HEM, URN,SEX | | | | | | | | | | | 314.2 | L02AA02 | polyestradiol fosfát | parent. | 1 | MG | 3,18 | B/ONK,HEM, URN,SEX | | | | | | | | | | | 314.3 | L02AA04 | fosfestrol | parent. | 0.1 | GM | 4,79 | B/ONK,HEM, URN,SEX | | 315 | L02AB | progestiny | p.o. | L/ONK,HEM,URN GYN,SEX | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 315.1 | L02AB01 | megestrol (pevné lékové formy) | p.o. | 160 | MG | 46,90 | L/ONK,HEM, URN GYN,SEX | | 86059 | MEGACE | tbl 100x160mg | BMS | D | | | | | 86211 | MEGACE | tbl 100x40mg | BMS | D | | | | | 315.2 | L02AB01 | megestrol (tekuté lékové formy) | p.o. | 160 | MG | 70,97 | P | | 53145 | MEGACE 40 MG/ML | sus por 1x240ml | | BMS | USA | | |
Indikováno v případech kachexie u manifestního AIDS a v případech, kdy nádorová kachexie je kontraindikací kurativní protinádorové terapie.
| 315.3 | L02AB02 | medroxypro-gesteron | p.o. | 1 | GM | 175,96 | L/ONK,HEM,URN GYN,SEX | | 58390 | PROVERA 500MG | tbl 20x500mg | PUA | I | | | | | 58392 | PROVERA 100MG | tbl 100x100mg | PUA | I | | | | | 316 | L02AB | progestiny | parent. | L/ONK,GYN,SEX | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 316.1 | L02AB02 | medroxypro-gesteron | parent. | 1 | GM | 786,00 | L/ONK,GYN,SEX | | 87805 | DEPO-PROVERA 150MG/ML | inj 1x1ml/150mg | UPJ | B | | | | | 316.2 | L02AB03 | gestonoron | parent. | 1 | MG | 1,12 | L/ONK,GYN,SEX | | 317 | L02AE | hormon uvolňující gonadotrofin a jeho deriváty | inhal. | Z | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 317.1 | L02AE01 | buserelin | inhal. | 1 | MG | 233,29 | Z | | 58106 | SUPRECUR | sol 1x10gm/15mg+apl | AVT | D | | | | | 58107 | SUPRECUR | sol 2x10gm/15mg+apl | AVT | D | | | | | 318 | L02AE | hormon uvolňující gonadotrofin a jeho deriváty | parent. | K/P | | | | | --- | --- | --- | --- | --- | --- | --- | --- |
Léčbu ordinuje onkolog, urolog, endokrinolog, dětský endokrinolog nebo gynekolog:
- a) léčba karcinomu prsní žlázy u premenopauzálních a perimenopauzálních žen, jen po dobu adjuvantní chemo- nebo radioterapie.
- b) léčba karcinomu prostaty,
- c) léčba myomatózy spojené s poruchou fertility nebo její těžké formy vyžadující předoperační redukci nálezu,
- d) léčba těžkých, jinak konzervativně nereagujících forem endometriózy,
- e) pubertas precox,
- f) indukce ovulace při in vitro fertilizaci pouze na základě předchozího schválení revizním lékařem.
Čtení tohoto dokumentu nenahrazuje čtení příslušného vydání Sbírky zákonů. Neneseme odpovědnost za případné nepřesnosti vyplývající z převodu originálu do tohoto formátu.
Tento text je zveřejněn za vlastních podmínek opětovného použití zdroje e-Sbírka, nikoli pod licencí Legalize ani pod licencí volného díla.
e-Sbírka
volné dílo (úřední díla podle § 3 písm. a) zákona č. 121/2000 Sb., autorského zákona)